IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies. (Q41511106)

From Wikidata

Jump to navigation Jump to search

scientific article published on January 2015

Language	Label	Description	Also known as
English	IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.	scientific article published on January 2015

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

Paolo M. Comoglio

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Eugenia R Zanella

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Francesco Galimi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Francesco Sassi

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Giorgia Migliardi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Francesca Cottino

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Simonetta M Leto

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Andrea Bertotti

15

object named as

Andrea Bertotti

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Barbara Lupo

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jessica Erriquez

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Eva Budinská

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Livio Trusolino

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sabine Tejpar

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

0 references

publication date

1 January 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Science Translational Medicine

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

272

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

272ra12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Which drug, and when, for patients with BRAF-mutant melanoma?

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Comprehensive molecular characterization of human colon and rectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

The insulin and insulin-like growth factor receptor family in neoplasia: an update

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Targeting the ERBB family in cancer: couples therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

LAS: a software platform to support oncological data management

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Cytogenetics and DNA amplification in colorectal cancers

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010445

21 January 2018

Identifiers

10.1126/SCITRANSLMED.3010445

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25632036%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41511106&oldid=1535989431"